eteplirsen

FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial
FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial
Endpoints
Sarepta Therapeutics
generics
Duchenne Muscular Dystrophy
FDA
eteplirsen
Flag link:
3 trends in biotech to watch in 2020
3 trends in biotech to watch in 2020
Stat
IPOs
eteplirsen
CAR-T
gene therapy
cell therapy
biotech
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
Endpoints
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta May Have More Upside After Sales Data
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug - Boston Business Journal
Bizjournals.com
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
eteplirsen
Flag link:
FDA emails show how upset some officials were over the Sarepta approval
FDA emails show how upset some officials were over the Sarepta approval
Stat/Pharmalot
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Flag link:
After Sarepta win, BioMarin appeals DMD patent ruling
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
Flag link:
FDA commissioner calls for Sarepta drug study to be retracted
FDA commissioner calls for Sarepta drug study to be retracted
Stat/Pharmalot
FDA
Sarepta Therapeutics
Robert Califf
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta's New Drug May Make It a Takeover
Sarepta's New Drug May Make It a Takeover
Investopedia
Sarepta Therapeutics
eteplirsen
Duchenne Muscular Dystrophy
M&A
Flag link:
Sarepta, Patients Win - But What Of Regulatory Oversight?
Sarepta, Patients Win - But What Of Regulatory Oversight?
Seeking Alpha
Sarepta Therapeutics
regulatory
Duchenne Muscular Dystrophy
FDA
eteplirsen
Flag link:
Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says
Stat/Pharmalot
Sarepta Therapeutics
Duchenne Muscular Dystrophy
drug pricing
eteplirsen
Flag link:
Behind the Sarepta drug approval was intense FDA bickering
Behind the Sarepta drug approval was intense FDA bickering
Stat/Pharmalot
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy
Stat
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Flag link:
Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?
Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?
Barron's
Sarepta Therapeutics
FDA
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
Sarepta Drug Critic Departs FDA, Raising Hope for Approval
Sarepta Drug Critic Departs FDA, Raising Hope for Approval
TheStreet.com
Sarepta Therapeutics
FDA
eteplirsen
Duchenne Muscular Dystrophy
Flag link:
10 Must-Know Biotech Stock Events to Close Out 2016
10 Must-Know Biotech Stock Events to Close Out 2016
TheStreet.com
biotech
Eli Lilly
solanezumab
Biogen
aducanumab
Kite Pharma
KTE-C19
Bluebird Bio
LentiGlobin
Sarepta Therapeutics
eteplirsen
Ophthotech
Fovista
Bristol-Myers Squibb
Opdvio
Acadia
Nuplazid
Celgene
GED-301
Gilead Sciences
M&A
Flag link:
3 Biotech Stocks With Explosive Upside Potential
3 Biotech Stocks With Explosive Upside Potential
Motley Fool
Acadia
Nuplazid
Radius Health
abaloparatide-SC
Sarepta Therapeutics
eteplirsen
Flag link:

Pages